Medtronic, Hansen to present clinical trial data at VEITHSymposium

Medtronic (NYSE:MDT) and Hansen Medical (NSDQ:HNSN) said they are slated to present new clinical information at this year’s annual VEITHSymposium in New York City.

Medtronic said today it plans to present 4-year subset data results from the ENGAGE global registry study of its Endurant AAA stent graft system.

The trial analyzed patients with hostile neck anatomies treated with the abdominal aortic aneurysm stent graft system, the Fridley, Minn.-based company said.

The company said it will present data in 9 separate presentations on its EndoAnchor system, which it obtained in its $110 million purchase of Aptus Endosystems in June.

“Leveraging decades of clinical experiences and data, our core technologies for treating abdominal aortic aneurysm and descending thoracic disease, Endurant and Valiant product lines, have been proven in more than 280,000 patients globally. Our mission to improve patient outcomes drives our commitment to build on our success and invest in complementary innovative technology that will allow physicians to treat more complex aortic disease,” Medtronic aortic biz gm Daveen Chopra said in a press release.

Medtronic is slated to present data on modified Valiant devices used to treat ascending arch disease, 1-year results from a feasibility trial of its Valiant Mona LSA branch thoracic stent graft system and initial experience data in treating thoracoabdominal with modified versions of the company’s stent grafts.

Hansen Medical said its Magellan robotic system will be featured in 8 scheduled presentations at the conference.

The Mountain View, Calif.-based company’s robotic catheter is designed to navigate the peripheral vasculature and provide a conduit for the placement of therapeutic devices, Hansen Medical said. The catheter operates as part of Hansen’s Magellan robotic system.

“We are delighted to be exhibiting at this year’s VEITHsymposium, and are particularly pleased with the robust representation of intravascular robotics on-podium. We are further excited to demonstrate our full complement of Magellan Robotic Catheters, particularly our latest addition, the Magellan 10Fr,” Hansen Medical CEO Cary Vance said in a prepared statement.

The conference beings tomorrow and runs through Saturday, according to its website.

The post Medtronic, Hansen to present clinical trial data at VEITHSymposium appeared first on MassDevice.

from MassDevice http://ift.tt/1N7yN9O